About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rhythm Pharmaceuticals, Inc. - Common Stock (NQ:RYTM)

105.11 +2.33 (+2.26%)
Streaming Delayed Price Updated: 1:29 PM EDT, Aug 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Rhythm Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Rhythm Pharmaceuticals Q2 Earnings Call Highlights ↗
Rhythm Pharmaceuticals (NASDAQ:RYTM) reported second-quarter 2026 global net product sales of $71.3 million for IMCIVREE, up 19% sequentially from $60.1 million in the first quarter, as the company... 
Via MarketBeat
Topics Earnings
News headline image
Full Transcript: Rhythm Pharmaceuticals Q2 2026 Earnings Call ↗
Rhythm Pharmaceuticals (NASDAQ:RYTM) released second-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. Benzinga APIs provide real-time access to... 
Via Benzinga
Topics Earnings
News headline image
My Top 3 Stocks to Buy in May ↗
Forget "sell in May and go away." These stocks are good picks to buy and hold. 
Via The Motley Fool
Topics Earnings
News headline image
Rhythm Pharmaceuticals Analysts Boost Their Forecasts Following Upbeat Q1 Results ↗
Rhythm Pharmaceuticals (NASDAQ: RYTM) reported better-than-expected earnings, with strong demand for IMCIVREE and potential launches in Europe and Japan. 
Via Benzinga
Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) Surpasses Q1 Estimates as U.S. Hypothalamic Obesity Launch Accelerates ↗
Via Chartmill
Rhythm Pharmaceuticals (NASDAQ:RYTM) Posts Q4 Revenue Beat and Narrows Loss ↗
Via Chartmill
RYTM Stock Jumps 4% On Imcivree Revenue Growth: Firm Awaits Approval In Acquired Hypothalamic Obesity By March ↗
Via Stocktwits
News headline image
Rhythm (RYTM) Q1 2026 Earnings Call Transcript ↗
Rhythm (RYTM) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Why Rhythm Pharmaceuticals Stock Triumphed on Tuesday ↗
It released an encouraging quarterly earnings report and business update before market open. 
Via The Motley Fool
News headline image
Neurocrine Biosciences to Acquire Celeno Therapeutics in Rare Disease Deal
In a move that signals a significant consolidation within the rare endocrine disease market, Neurocrine Biosciences (NASDAQ: NBIX) announced on April 6, 2026, that it has entered into a definitive... 
Via MarketMinute
News headline image
Soleno Therapeutics: A Masterclass in Rare Disease Redemption and the $2.9B Exit
The following feature explores the trajectory of Soleno Therapeutics as of April 7, 2026. Introduction On the morning of April 7, 2026, the biotechnology sector is processing one of the most... 
Via Finterra
Topics Economy Intellectual Property
News headline image
Neurocrine Biosciences to Acquire Soleno Therapeutics in $2.9 Billion Deal as VYKAT™ XR Sales Soar
Shares of Soleno Therapeutics (NASDAQ: SLNO) surged more than 32% in early trading on Monday, April 6, 2026, following the blockbuster announcement that Neurocrine Biosciences (NASDAQ: NBIX) has... 
Via MarketMinute
Topics Intellectual Property
News headline image
Is This Weight Loss Drug Stock a Buy After a New Approval? ↗
This little-known biotech company has a different strategy than the established weight-loss drug market leaders. But is it likely to be successful? 
Via The Motley Fool
News headline image
Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing ↗
Immunome develops antibody therapeutics for cancer and infectious diseases, reporting a market cap above $2 billion in the latest filing. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing ↗
Liquidia develops inhaled and injectable therapies for pulmonary arterial hypertension, targeting unmet needs in the U.S. biopharma market. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Rhythm Pharma (RYTM) Earnings Call Transcript ↗
Rhythm Pharma (RYTM) Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million ↗
Praxis Precision Medicines targets neurological and psychiatric disorders with a pipeline of precision therapies for CNS conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position ↗
Celcuity develops targeted cancer therapies and diagnostic platforms, with a focus on advancing precision medicine in oncology. 
Via The Motley Fool
News headline image
Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction ↗
Apogee Therapeutics develops biologic therapies targeting dermatology and respiratory conditions, with lead candidates in clinical trials. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges ↗
Arcellx develops next-generation cell therapies targeting multiple myeloma and other hematologic cancers in the biotechnology sector. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Prediction: These 3 Stocks Will Crush the Market in 2026 ↗
These stocks all have catalysts on the way that could provide great news for investors. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
This High-Flying Growth Stock Is Hiding in Plain Sight ↗
This biotech stock is flying under the radar for many investors, but Wall Street loves it. 
Via The Motley Fool
News headline image
The Great Divergence: Why Big Tech Holds the Line While Logistics and Biotech Face a 2026 Reckoning
As the curtain closes on 2025, the financial landscape presents a tale of two markets. While the S&P 500 (NYSEARCA: SPY) hovers near the historic 7,000-point milestone, fueled by a 19% year-to-date... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Rhythm Pharmaceuticals Faces Gravity: FDA Delays and Valuation Pressures Cool 2025’s Biotech Darling
As the final trading days of 2025 wind down, Rhythm Pharmaceuticals (Nasdaq: RYTM) finds itself at a critical crossroads. After a meteoric rise that saw the stock gain over 100% through the first three... 
Via MarketMinute
Topics ETFs Economy World Trade
News headline image
Rhythm Pharmaceuticals Stock Rises After Positive Study Data For Setmelanotide In Treating Genetic Disorder ↗
The company was studying the therapy in Prader-Willi Syndrome, a rare genetic disorder requiring lifelong management. 
Via Stocktwits
News headline image
The market is filled with gapping stocks in Thursday's session. ↗
Let's have a look at the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
News headline image
These stocks are moving in today's after hours session ↗
The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
News headline image
Rythm Pharmaceuticals' (RYTM) Chief Technical Officer Sells 9,748 Shares for $1.1 Million ↗
Rythm Pharmaceuticals' (RYTM) Chief Technical Officer Sells 9,748 Shares for $1.1 Million 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Rhythm Pharmaceuticals (NASDAQ:RYTM) Reports Mixed Q3 2025 Results ↗
Rhythm Pharmaceuticals posts mixed Q3 2025 results, missing revenue estimates. Despite the loss, the company highlights strong drug growth and key regulatory milestones for its obesity treatments. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.